Hot Topics in Dyslipidemia From the 2018 American College of Cardiology Scientific Sessions
Module 1: Hot Topics in Dyslipidemia From the 2018 American College of Cardiology Scientific Sessions
This CME-accredited CME Snapshot™ seven-part series is intended for interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and other diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia. During these activities, expert faculty will participate in a series of interactive discussions on the latest evidence and their clinical experience managing patients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels using nonstatin lipid-lowering medications, including inhibitors of the enzyme protein convertase subtilisin/kexin type 9 (PCSK9).
These activities have been designed to meet the educational needs of interventional cardiologists, other cardiologists, lipidologists, endocrinologists, and diabetologist physicians involved in the ongoing management of patients with persistent hypercholesterolemia.
Upon completion of these activities, participants should be better able to do the following:
- Adapt their clinical decision-making for the management of patients with persistent hypercholesterolemia based on newly published data from key 2018 medical conferences.
- Describe study designs and available evidence from recent long-term cardiovascular outcomes trials examining nonstatin lipid-lowering medications, including clinical implications of published data for various patient types.
Deepak L. Bhatt, MD, MPH
Christopher P. Cannon, MD
Disclosure of Conflicts of Interest
It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of these educational activities.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interests related to the content of these CME activities:
|Name of Faculty or Presenter|
Relationship Identified With:
Deepak L. Bhatt, MD, MPH
Grant/Research: Abbott Laboratories, Amarin Corporation, Amgen Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Chiesi USA, Inc., Eisai Inc., Ethicon US, LLC, Forest Laboratories, Inc., Ironwood Pharmaceuticals, Inc., Ischemix, Inc., Eli Lilly and Company, Medtronic PLC, Pfizer Inc., F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc., sanofi-aventis U.S. LLC, The Medicines Company
Christopher P. Cannon, MD
Grant/Research: Amgen Inc., Arisaph Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Daiichi Sankyo Company, Limited, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Takeda Pharmaceuticals U.S.A., Inc.; Consulting: Alnylam Pharmaceuticals, Inc., Amarin Corporation, Amgen Inc., Arisaph Pharmaceuticals, Inc., AstraZeneca plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eisai Inc., GlaxoSmithKline plc, Kowa Pharmaceuticals America, Inc., LipoMedix Pharmaceutical Inc. , Merck & Co. Inc., Pfizer Inc., Regeneron Pharmaceuticals, Inc., sanofi-aventis U.S. LLC, Takeda Pharmaceuticals, U.S.A., Inc.
Non-faculty: Jim Kappler, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouses/life partners have any financial relationships to products or devices with any commercial interest related to the content of these activities of any amount during the past 12 months.
These activities have been supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
Jointly provided by the Elsevier Office of Continuing Medical Education and Integritas Communications in collaboration with the American Journal of Cardiology.
CME Credit (Physicians)
These activities have been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Integritas Communications. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in each activity.
CME Inquiries/Special Needs
For all CME inquiries or special needs, please contact elsevierCME@elsevier.com.
Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The Elsevier Office of Continuing Medical Education, Integritas Communications, and Sanofi US and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
- 0.50 AMA PRA Category 1 Credit(s)™
- 0.50 Non-physician